GLPwatch
Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.
Prog Cardiovasc Dis · 2021
Last updated 2026-07-30| Journal | Prog Cardiovasc Dis, 2021 |
|---|---|
| Citations | 16 |
| Relative citation ratio | 1.01 |
| NIH percentile | 51 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 34560122 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.